explore -WSS

explore

author：comprehensive 2025-09-27 23:51:50 - browse：4362

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration said Monday that it has deep reservations about NurOwn, an investigational ALS treatment from BrainStorm Cell Therapeutics, citing a lack of evidence that the medicine works and the company’s failure to demonstrate that it can properly manufacture the product.

In documents disclosed ahead of a Wednesday public hearing on NurOwn’s application for approval, the FDA detailed its problems with a clinical trial that missed its primary objective and noted that BrainStorm submitted “grossly deficient” information on how the medicine is made, voicing “major concerns that the available data do not meet the statutory standard of substantial evidence of effectiveness to support” approval.

BrainStorm filed for approval over the FDA’s protest, insisting that NurOwn has demonstrated benefits for a subset of ALS patients with milder disease. That conclusion, based on an after-the-fact analysis of the company’s failed pivotal trial, has proved polarizing among patients and physicians, with some arguing that the FDA should exercise flexibility in light of the irrevocably fatal nature of ALS and others demanding BrainStorm conduct another clinical trial to demonstrate its benefits.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Caregivers of transplant patients call for more support, training

WSS

Fauci’s Covid grilling leads GOP to weigh foreign research rules

Pharma patents targeted by Biden in move to slash drug prices

The nurse manager staffing crisis is hurting patients

The woman behind the Dana Farber

Supreme Court wrestles with OxyContin maker's bankruptcy deal

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

explore

explore

leisure time

Heart attack and stroke risk calculators need revising

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

Anesthesiologist group: stop taking Ozempic before surgery

As JPM 2024 winds down, some health tech firms project optimism

Guidelines to prevent youth baseball injuries need more muscle

AI models in health care face new federal disclosure requirements

The cancer drug shortage isn’t new — and neither are the solutions

Radiology is caught between AI's potential and concern for patients

Supreme Court strikes down use of affirmative action

Risky weight loss products often used by teens globally, per study

focus

SCOTUS to consider access to abortion pill mifepristone

Radiology is caught between AI's potential and concern for patients

Caregivers of transplant patients call for more support, training

Fauci’s Covid grilling leads GOP to weigh foreign research rules

New Medicare drug pricing powers could soon be upended in court

Heart disease and mental health: A look at cardiac psychology

leisure time

hotspot

hotspot

leisure time